A biopharmaceutical company engaged in developing treatments for rare diseases, with a focus on various forms of asthma, including allergic and intrinsic types.
0
Orphan Designations
34
FDA Approvals
Latest: BILPREVDA (2025)
0
Active Trials
6
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Organon LLC is a company with 0 orphan drug designations across 6 rare diseases, including 34 FDA-approved therapies. 2 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| allergic asthma | DULERA | Des.TrialAppr. |
| asthma | DULERAASMANEX | Des.TrialAppr. |
| cough variant asthma | DULERA | Des.TrialAppr. |
| intrinsic asthma | DULERA | Des.TrialAppr. |
| osteoporosis | FOSAMAX PLUS D | Des.TrialAppr. |
| status asthmaticus | DULERA | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
2
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/6
candidate diseases
0
avg importance: 0
2
affecting portfolio